Physician profile
Sharon A Meyer
NPI 1427456318
$3,831.24
in general payments reported to CMS, 2019-2025
21 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.90 · 2022: $20.70 · 2023: $591 · 2024: $1,964 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,793.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,191.22 | 2021-2025 | |
| Genzyme Corporation | $342.85 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $342.00 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Ardelyx, INC. | $340.14 | 2023-2025 | Ibsrela |
| Janssen Biotech, INC. | $333.90 | 2024-2025 | Tremfya, Stelara |
| Braintree Laboratories, INC. | $222.64 | 2023-2025 | Sutab, Suflave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.66 | 2024-2025 | Trulance, Xifaxan, Relistor |
| Phathom Pharmaceuticals, INC. | $141.86 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $133.54 | 2024-2025 | Iqirvo |
| E.R. Squibb & Sons, L.L.C. | $117.06 | 2024 | Zeposia |
| Madrigal Pharmaceuticals | $117.00 | 2025 | Rezdiffra |
| Lilly USA, LLC | $94.38 | 2023-2024 | Omvoh |
| Qol Medical, LLC | $77.34 | 2024-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $64.71 | 2024-2025 | Dupixent |
| Pfizer INC. | $39.10 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $27.64 | 2024 | |
| Mirum Pharmaceuticals, INC. | $23.60 | 2025 | Livmarli |
| Redhill Biopharma INC. | $21.55 | 2024 | Talicia |
| Novo Nordisk INC | $20.89 | 2025 | Wegovy |
| Vivus LLC | $18.14 | 2024 | Pancreaze |
| Evoke Pharma, INC. | $18.02 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.